taminadenant

Taminadenant is a highly potent and selective small molecule antagonist of the adenosine A2A receptor (ADORA2A). It is orally bioavailable and has been developed primarily for oncology indications. By blocking the immunosuppressive effects mediated by adenosine in the tumor microenvironment, taminadenant can reactivate antitumor immune responses. Preclinical studies have shown that it inhibits cAMP accumulation via A2A receptor antagonism and reduces tumor growth in xenograft models. Taminadenant has also been investigated as a potential pro-dopaminergic agent for Parkinson’s disease but its main clinical development has focused on solid tumors such as non-small cell lung cancer (NSCLC) and diffuse large B cell lymphoma. The drug was originally discovered by Palobiofarma and further developed in collaboration with Novartis

Brand names

taminadenant

Other names

4-pyrimidinamine, 5-bromo-2,6-di-1h-pyrazol-1-yl-